New AI diagnostic, Vitara Pancreas ChemoPredict, can select optimal first-line treatment for advanced pancreatic cancer patients. Valar Labs, ...
Australian company Ferronova announced it has completed enrolment of patients for its two-year trial to progress commercialisation of FerroTrace, a ...
In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significant...
eyonis® LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unne...
Decision removes last patent hurdle as Geneoscopy advances ColoSense®, its RNA-based noninvasive colorectal cancer screening test Geneosco...
Ascentage Pharma Group International , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commerc...
Novel approach attacks production of polyamines that tumors require to proliferate and suppress the immune system Aminex Therapeutics, Inc., a...
Initiative will create one of the world's largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel p...
Dr. Albert Bourla, Chairman and CEO of Pfizer, said: “With excellent execution in 2025, we delivered a solid financial performance and strengt...
Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...
Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel trea...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecos...
Parse Biosciences and Graph Therapeutics (Graph) announced a strategic partnership to create one of the largest and most comprehensive immune cell pertur...
Based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s ENHERTU in combination with pertuzumab significant...
© 2026 Biopharma Boardroom. All Rights Reserved.
